Why the study?
Integration of cardioneuroablation for vasovagal syncope into standard clinical guidelines has been impeded by the lack of placebo-controlled randomized controlled trials.
Does cardioneuroablation improve outcomes in patients with vasovagal syncope?
Does cardioneuroablation improve outcomes in patients with vasovagal syncope?
This review highlights the need for standardized, multicenter, placebo-controlled RCTs to validate the efficacy of cardioneuroablation for vasovagal syncope.
CNA may benefit refractory VVS; leaves open guideline integration pending placebo-controlled RCTs.
Vasovagal syncope (VVS), a common autonomic disorder, often sees limited effectiveness with conventional treatments. Cardioneuroablation (CNA), which targets the cardiac ganglionated plexi to modulate heart rate and rhythm, has surfaced as a potential alternative. Despite positive outcomes in clinical trials, the integration of CNA into standard clinical guidelines has been impeded by the lack of placebo-controlled randomized controlled trials (RCTs) — the gold standard for the validation of new clinical interventions. This review scrutinizes the various techniques for mapping the ganglionated plexi, crucial for the efficacy of CNA, and calls for the establishment of standardized, multicentre RCTs to confirm CNA's true therapeutic value.
No takes yet. Share an insight, caveat, or question.
Zuhair et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: